Agreement includes therapeutic and preventive candidates against HIV, HCV, HPV, and herpes simplex virus.
Profectus BioSciences obtained from Wyeth Pharmaceuticals therapeutic/prophylactic vaccine programs for HIV, HCV, HPV, and herpes simplex virus.
Profectus reports that the assignment and license agreement also provides it with access to an extensive portfolio of intellectual property, research reagents, equipment, governmental funding, and clinical trial products.
The licensed programs leverage Wyeth’s technologies in the fields of DNA and vectored vaccines that can be used alone or in a prime-boost strategy to prevent and treat infections. “The breadth and strength of the Wyeth portfolio coupled with our expertise will enable us to deliver a new class of vaccines into infected individuals, with the first human trials projected to begin in 2009 for HIV followed closely by HCV,” notes Profectus president and CEO Shawn O’Brien.
